Business
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., December 23, 2025--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST.
About this update from Beone Medicines Ltd. Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":28492,"height":5743,"url":"https://media.zenfs.com/en/business-wire.com/a7bf725260c948e5007a6e6536ab152c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bQDq1WAd2FTqkP9Ea3AYcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a7bf725260c948e5007a6e6536ab152c","width":960,"height":194},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NK0LGtTZ8FCeyXx8D2E7mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a7bf725260c948e5007a6e6536ab152c","width":1200,"height":242}},"lazy":false},{"type":"text","content":"SAN CARLOS, Calif., December 23, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST.","length":299,"tagName":"p"},{"type":"text","content":"Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website.","length":261,"tagName":"p"},{"type":"text","content":"About BeOne Medicines","length":21,"tagName":"p"},{"type":"text","content":"BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.","length":549,"tagName":"p"},{"type":"text","content":"To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.","length":116,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements","length":26,"tagName":"p"},{"type":"text","content":"This press release...